Rating #8
Stanley Freeman Druckenmiller
Duquesne Family Office
Portfolio value
Stocks
Performance
1 Year
+34.13%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Stanley Freeman Druckenmiller’s Portfolio: Q4 2025
Top10 stocks: 52.29% of the portfolio
Stanley Freeman Druckenmiller’s Trades: Q4 2025
Adds
New Buys
Sold Outs
Cuts
S
Share Count Chg. (%)
Add +100.00%
6.70ppt
I
Share Count Chg. (%)
Add +100.00%
2.51ppt
1.47ppt
2.07ppt
1.58ppt
1.43ppt
-0.12ppt
1.20ppt
1.05ppt
1.01ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1 S XLF | Add +100.00% | $53.28 | $292.81M | 6.70ppt | |
2 I EWZ | Add +100.00% | $31.62 | $112.33M | 2.51ppt | |
3  SE | Add +244.32% | $148.11 | $99.22M | 1.47ppt | |
Add +276.71% | $285.73 | $80.80M | 2.07ppt | ||
5  ENTG | Add +100.00% | $86.87 | $73.33M | 1.58ppt | |
6  AMZN | Add +68.84% | $228.79 | $68.84M | 1.43ppt | |
7  CPNG | Add +46.18% | $28.45 | $60.88M | -0.12ppt | |
8  TBBB | Add +126.11% | $29.90 | $44.61M | 1.20ppt | |
9  NAMS | Add +59.60% | $36.39 | $41.72M | 1.05ppt | |
10  DAL | Add +100.00% | $62.48 | $40.67M | 1.01ppt |
Stanley Freeman Druckenmiller’s Holdings: Q4 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1  NTRA | Medical Laboratories | $99.19 | Cut -21.87% | 2.51M | $575.33M | 12.80% 0.06ppt | 1.83% | 14 Quarters | Q4 2025 | |
2 S XLF | - | $54.77 | Add +100.00% | 5.50M | $300.99M | 6.70% 6.70ppt | 0.54% | 3 Quarters | Q4 2025 | |
3  INSM | Pharmaceutical Pres | $88.13 | Cut -38.86% | 1.48M | $257.88M | 5.74% -2.85ppt | 0.70% | 7 Quarters | Q4 2025 | |
4 I RSP | - | $191.56 | New Buy +100.00% | 1.17M | $224.88M | 5.00% 5.00ppt | 0.27% | 1 Quarter | Q4 2025 | |
5  TEVA | Pharmaceutical Pres | $18.91 | Cut -64.60% | 5.87M | $183.36M | 4.08% -4.17ppt | 0.51% | 6 Quarters | Q4 2025 | |
6  WWD | Industrial Apparatus | $150.85 | Cut -6.65% | 590.93K | $178.65M | 3.97% 0.04ppt | 0.99% | 9 Quarters | Q4 2025 | |
7 AMZN | Retail-Catalog & Mail-Order | $224.16 | Add +68.84% | 737.94K | $170.33M | 3.79% 1.43ppt | 0.01% | 5 Quarters | Q4 2025 | |
8  TSM | Semiconductors | $181.79 | Cut -29.02% | 543.09K | $165.04M | 3.67% -1.59ppt | 0.01% | 6 Quarters | Q4 2025 | |
9 CPNG | Retail-Catalog & Mail-Order | $30.64 | Add +46.18% | 6.77M | $159.77M | 3.55% -0.12ppt | 0.37% | 20 Quarters | Q4 2025 | |
10 I EWZ Call | - | $31.77 | New Buy +100.00% | 4.23M | $134.32M | 2.99% 2.99ppt | - | 1 Quarter | Q4 2025 | |
11  GOOGL | Computer Programming & Data | $294.44 | Add +276.71% | 385.00K | $120.51M | 2.68% 2.07ppt | 0.00% | 2 Quarters | Q4 2025 | |
12 SE | Misc. Business Services | $136.97 | Add +244.32% | 944.12K | $120.44M | 2.68% 1.47ppt | 0.16% | 3 Quarters | Q4 2025 | |
13 I EWZ | - | $31.77 | Add +100.00% | 3.55M | $112.87M | 2.51% 2.51ppt | 1.77% | 3 Quarters | Q4 2025 | |
14 NAMS | Pharmaceutical Pres | $28.37 | Add +59.60% | 3.07M | $107.70M | 2.40% 1.05ppt | 2.58% | 6 Quarters | Q4 2025 | |
15  MELI | Other Business Services | $1756.50 | Cut -19.19% | 47.15K | $94.97M | 2.11% -1.24ppt | 0.09% | 7 Quarters | Q4 2025 | |
16 TBBB | Retail-Grocery Stores | $30.65 | Add +126.11% | 2.68M | $89.32M | 1.99% 1.20ppt | 2.32% | 3 Quarters | Q4 2025 | |
17  QSR | Eating places | $65.74 | Add +6.86% | 1.21M | $82.49M | 1.84% 0.05ppt | 0.36% | 3 Quarters | Q4 2025 | |
18  COGT | Pharmaceutical Pres | $25.40 | Add +109.00% | 2.21M | $78.66M | 1.75% 1.38ppt | 3.28% | 2 Quarters | Q4 2025 | |
19  AA | - | $53.14 | New Buy +100.00% | 1.38M | $73.12M | 1.63% 1.63ppt | 0.53% | 1 Quarter | Q4 2025 | |
20 ENTG | Other Plastic Products | $84.25 | Add +100.00% | 844.16K | $71.12M | 1.58% 1.58ppt | 0.56% | 3 Quarters | Q4 2025 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.